-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IPP-204106 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPP-204106 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IPP-204106 in Metastatic Breast Cancer Drug Details: IPP-204106 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Forigerimod Acetate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Forigerimod Acetate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IPP-204106 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPP-204106 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IPP-204106 in Bladder Cancer Drug Details:IPP-204106 is under development for the treatment of...
-
Company Profile
Immupharma Plc – Company Profile
ImmuPharma Plc (ImmuPharma) is a biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; BioCIN, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and P140, a drug developed for the treatment of Chronic Inflammatory...
Add to Basket -
Product Insights
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The Age...
-
Product Insights
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections. The Bladder Cancer pipeline market research report provides comprehensive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – forigerimod acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry forigerimod acetate Drug Details Forigerimod (lupuzor, IPP-201101, rider mod or P140) is under development...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The risk factors of Methicillin-Resistant Staphylococcus Aureus (MRSA) are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed using antibiotics and by maintaining hygienic conditions The Methicillin-Resistant Staphylococcus Aureus pipeline market research report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus Aureus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...